title: Ingenol Mebutate 500 μg for Treatment of the Scalp in Refractory Field Cancerization.
abstract: Patients suffering from chronic lymphocytic leukemia often develop actinic keratosis (AK) and squamous cell carcinoma in sun-exposed areas. In these particular patients, who have a suboptimal immune function, AK treatment can be particularly challenging. We report the case of a patient who failed to respond to most AK treatments, including 5-FU, imiquimod and photodynamic therapy, but responded to ingenol mebutate. We started with 3 applications of 150 μg/g (registered treatment of the scalp) and also 2 applications of 500 μg/g (registered in for trunk and extremities). Both treatments were well tolerated, but only the latter led to significant clinical success. This suggests that 500 μg/g of ingenol mebutate may represent an interesting therapeutic option in patients with mild immunosuppression.
authors: Department of Dermatology and Venerology, CHUV, Lausanne, Switzerland.
authors: Olivier
authors: O
authors: Gaide
authors: Helena
authors: H
authors: Clayton
authors: Marie
authors: M
authors: Girardin
authors: Francois
authors: F
authors: Kuonen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D063646:Carcinogenesis / Q000187:drug effects*; D002280:Basal Cell Carcinoma / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D004224:Diterpenes / Q000008:administration & dosage*; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000276:immunology*; D008297:Male; D012535:Scalp; D012878:Skin Neoplasms / Q000628:therapy*
chemical_list: C486592:3-ingenyl angelate; D000970:Antineoplastic Agents; D004224:Diterpenes